Supplementary
. Study samples. Study samples for the meta-analysis and replication studies were ascertained in the United States (US) and central Europe. All US cases were ascertained through the National Alopecia Areata Registry (NAAR). The US cases included in the meta-analysis are the same cohort previously reported in our initial Genomewide Association Study (GWAS).
1 The US controls used in the meta-analysis are the same cohorts used in our initial GWAS, 1 and were ascertained through the New York Canter Project 2 or the Cancer Genetic Markers of Susceptibility (CGEMS) breast 3 and prostate 4 cancer studies. The US cases used in the replication study are an independent sample of NAAR participants who self-report European ancestry. US controls for the replication study were either ascertained through NAAR (Sequenom genotyping) or were obtained from the NIDDK inflammatory bowel disease (IBD) genetics consortium (http://medicine.yale.edu/intmed/ibdgc/index.aspx) (ImmunoChip genotyping). The cohorts ascertained in central Europe had not been used in any previously published GWAS. Cases and controls were ascertained from outpatient clinics, private dermatology practices and via AA self-support groups in Belgium and Germany. Inclusion criteria followed published guidelines, , and the Heinz Nixdorf Recall (HNR) Study 8 and an additional population-based cohort from the HNR 8 study. 

